molecule.one
molecule.one is an AI-driven biotechnology company focused on autonomous chemical synthesis and drug discovery. Founded in 2016 and headquartered in Warsaw, Poland, with a presence in San Francisco, the company utilizes proprietary AI technologies, including Maria™ and SpaceM1, to enhance pharmaceutical manufacturing and drug discovery processes. The company offers a range of services, including custom organic synthesis, a virtual library of over 1 trillion drug-like molecules, and AI-driven synthesis planning. Their laboratory can perform up to 60,000 reactions monthly, enabling rapid access to complex compounds and optimizing drug discovery pipelines. molecule.one serves the B2B pharmaceutical and biotechnology sectors, helping clients accelerate drug development and improve efficiency through high-accuracy predictions and streamlined processes. Recognized as a leader in chemical AI, molecule.one has received funding from notable investors and has been awarded for its advancements in predictive chemistry systems.